Angeliq Regulatory Post Marketing Surveillance.
Phase of Trial: Phase IV
Latest Information Update: 18 Nov 2013
At a glance
- Drugs Estradiol/drospirenone (Primary)
- Indications Menopausal syndrome; Postmenopausal osteoporosis
- Focus Adverse reactions
- Acronyms Angeliq rPMS
- Sponsors Bayer
- 01 Dec 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 19 Feb 2010 New trial record